Ticagrelor has a faster onset and more consistent platelet inhibition than clopidogrel because:

• A Ticagrelor also inhibits P2Y1 receptors, providing additional antiplatelet effect
• B Ticagrelor directly inhibits thromboxane synthase in addition to P2Y12 blockade
• C Ticagrelor is a direct-acting, reversibly-binding P2Y12 antagonist that does not require CYP2C19-mediated activation; clopidogrel is a prodrug requiring CYP2C19 for active metabolite formation ✓
• D Ticagrelor undergoes hepatic first-pass extraction that concentrates it in portal blood supplying the spleen where platelet sequestration occurs

Explanation

Clopidogrel is a thienopyridine prodrug requiring two-step hepatic metabolism by CYP2C19 to form its active thiol metabolite, which then irreversibly blocks P2Y12. CYP2C19 loss-of-function polymorphisms (common in East Asians, ~30–40%) produce poor metabolizers with inadequate platelet inhibition and worse cardiovascular outcomes — the basis of FDA's black-box warning. Ticagrelor is a cyclopentyl-triazolopyrimidine (CPTP class) that is itself active (not a prodrug), binds P2Y12 reversibly at an allosteric site (not the ADP binding site), and shows consistent platelet inhibition regardless of CYP2C19 genotype. PLATO trial showed superiority of ticagrelor over clopidogrel in ACS.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.